头颈部横纹肌肉瘤减少环磷酰胺剂量导致更差结局
该单机构队列研究纳入2000至2018年76例接受根治性放化疗的儿童头颈部横纹肌肉瘤患者,其中51例(67%)接受调强光子放疗、25例(33%)接受质子治疗,分析局部控制与生存结局及环磷酰胺剂量对疾病结局的影响。结果显示2年局部失败在脑膜旁横纹肌肉瘤为12.5%、眶部及其他头颈部部位为0%(P=0.24),累积环磷酰胺剂量>20 g/m2组2年局部失败为0% vs ≤20 g/m2组15.3%(P=0.04)。
要点
- 2年局部失败:脑膜旁横纹肌肉瘤12.5%,眶部及其他头颈部部位0%(P=0.24)。
- 累积环磷酰胺剂量>20 g/m2组2年局部失败0% vs ≤20 g/m2组15.3%(P=0.04)。
- 脑膜旁横纹肌肉瘤中累积剂量与剂量强度均与局部失败相关(P=0.01)。
核心结论
- 剂量强度和累积环磷酰胺剂量似乎在接受质子或光子治疗的头颈部横纹肌肉瘤患者实现局部控制中起重要作用。
- 质子治疗的疾病结局需更长时间随访进一步评估。
研究设计与样本
- 单机构队列研究,纳入2000至2018年76例接受根治性放化疗的儿童头颈部横纹肌肉瘤患者。
- 51例(67%)接受调强光子放疗,25例(33%)接受质子治疗。
主要发现
- 2年局部失败在脑膜旁横纹肌肉瘤为12.5%,眶部及其他头颈部部位为0%(P=0.24)。
- 质子治疗患者更可能接受减少剂量环磷酰胺(P<0.0001)。
- 2年局部失败在调强光子放疗队列为7.9% vs 质子队列14.6%(P=0.07),生存结局无差异。
- 累积环磷酰胺剂量与2年局部失败显著相关:>20 g/m2组0% vs ≤20 g/m2组15.3%(P=0.04)。
- 脑膜旁横纹肌肉瘤患者(n=59)中累积环磷酰胺剂量和剂量强度均与局部失败相关(P=0.01);接受减少剂量强度环磷酰胺者无事件生存有更差趋势(59.2% vs 70.6%,P=0.11)。
局限性
- 原文结论指出质子治疗的疾病结局需更长时间随访进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent trends, including the use of proton therapy and administration of reduced doses of cyclophosphamide, have been adapted in head and neck (HN) rhabdomyosarcoma (RMS) to reduce late morbidity. Our primary goal was to analyze local control and survival outcomes after photon versus proton irradiation in pediatric patients with HN-RMS, with the secondary goal of analyzing the effect of cyclophosphamide dose on disease outcomes. METHODS AND MATERIALS: This single-institution cohort study comprised 76 pediatric HN-RMS patients treated with definitive chemoradiation from 2000 to 2018. Fifty-one patients (67%) received intensity modulated photon radiation therapy, and 25 (33%) received proton therapy. RESULTS: Local failure (LF) at 2 years was 12.5% for parameningeal RMS and 0% for orbital RMS and other head and neck sites (P = .24). Patients treated with protons were more likely to have received reduced-dose cyclophosphamide (P < .0001). The 2-year LF was 7.9% in the intensity modulated photon radiation therapy cohort versus 14.6% in the proton cohort (P = .07), with no difference in survival outcomes. Cumulative cyclophosphamide dose was significantly associated with 2-year LF: 0% for cumulative dose of >20 g/m2 versus 15.3% for ≤20 g/m2 (P = .04). In parameningeal RMS patients (n = 59), both cumulative cyclophosphamide dose and dose intensity were associated with LF (P = .01). There was a trend toward worse event-free survival for parameningeal RMS patients who received reduced-dose-intensity cyclophosphamide (59.2% vs 70.6%, P = .11). CONCLUSIONS: Both dose-intensity and cumulative cyclophosphamide dose seem to play an important role in achieving local control for HN-RMS patients treated with either protons or photons. Longer follow-up is needed to further assess disease outcomes with proton therapy.
引用
- Casey DL, Wexler LH, Wolden SL, et al. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. Int J Radiat Oncol Biol Phys. 2018. PMID: 30508617. doi:10.1016/j.ijrobp.2018.11.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。